ADVERTISEMENT

404

Not Found

Is this what you were looking for?

tag twitter ecology disease medicine culture

bacteria and DNA molecules on a purple background.
Engineering the Microbiome: CRISPR Leads the Way
Mariella Bodemeier Loayza Careaga, PhD | Mar 15, 2024 | 10+ min read
Scientists have genetically modified isolated microbes for decades. Now, using CRISPR, they intend to target entire microbiomes.
A fruit bat in the hands of a researcher
How an Early Warning Radar Could Prevent Future Pandemics
Amos Zeeberg, Undark | Feb 27, 2023 | 8 min read
Metagenomic sequencing can help detect unknown pathogens, but its widespread use faces challenges.
Meeting of the Minds
Mary Beth Aberlin | Jul 1, 2012 | 3 min read
New changes at The Scientist will ensure that we continue to showcase the best and brightest ideas in the life sciences.
The Scientist Staff | Mar 28, 2024
A scanning electron micrograph of a coculture of E. coli and Acinetobacter baylyi. Nanotubes can be seen extending from the E. coli.
What’s the Deal with Bacterial Nanotubes?
Sruthi S. Balakrishnan | Jun 1, 2021 | 10+ min read
Several labs have reported the formation of bacterial nanotubes under different, often contrasting conditions. What are these structures and why are they so hard to reproduce?
The Proteasome: A Powerful Target for Manipulating Protein Levels
John Hines and Craig M. Crews | May 1, 2017 | 10+ min read
The proteasome’s ability to target and degrade specific proteins is proving useful to researchers studying protein function or developing treatments for diseases.
The Surgisphere Scandal: What Went Wrong?
Catherine Offord | Oct 1, 2020 | 10+ min read
The high-profile retractions of two COVID-19 studies stunned the scientific community earlier this year and prompted calls for reviews of how science is conducted, published, and acted upon. The warning signs had been there all along.
African Sleeping Sickness: A Recurring Epidemic
Ricki Lewis | May 12, 2002 | 5 min read
African trypanosomiasis is making an unwelcome comeback. But unlike other returning diseases, this one has a drug treatment—eflornithine—that disappeared from the market when it failed to cure cancer. Yet like Viagra's origin from a curious side effect in a clinical trial, so too was eflornithine reborn. "When it was discovered that it removes mustaches in women, it suddenly had a market: western women with mustaches," says Morten Rostrup, president of the international council for M
Top 10 Innovations 2014
The Scientist | Dec 1, 2014 | 10+ min read
The list of the year’s best new products contains both perennial winners and innovative newcomers.
Researchers Receiving MacArthur Fellowships Demonstrate 'Capacity To Make A Difference'
Bruce Anderson | Sep 14, 1997 | 6 min read
PRIZE WITH A PRICE: Science historian Peter Galison has taken some ribbing from his family since being named a MacArthur fellow. One could almost pity Peter Galison. A historian of science at Harvard University, Galison is one of seven members of the scientific community among the 23 recipients of this year's John D. and Catherine T. MacArthur Foundation Fellowships. The coveted five-year awards provide unrestricted support plus health insurance to talented individuals, with no reports or proj

Run a Search

ADVERTISEMENT